Rohan Reddy Katipally
Papers
1
Total Citations
12
H-Index
1
About
Dr. Rohan Reddy Katipally is a leading clinical researcher at the intersection of immunotherapy and head and neck oncology, with a primary focus on human papillomavirus (HPV)-associated oropharyngeal cancer (OPC). His work is pioneering novel strategies to leverage the unique viral biology of HPV16+ tumors for therapeutic benefit. Dr. Katipally’s major contribution is his leadership in the landmark TARGET-HPV trial, which investigates a paradigm-shifting approach: combining neoadjuvant chemotherapy with HB-200, a novel arenavirus-based immunotherapy designed to stimulate a potent HPV16-specific T-cell response. This study is critical for testing whether an intensified immune attack can allow for safe, response-stratified de-intensification of subsequent chemoradiation, thereby reducing long-term toxicity for patients. With this 2024 publication already garnering 12 citations, his work is rapidly shaping the conversation around curative-intent, biology-driven treatment for HPV-driven cancers. Dr. Katipally’s research is at the forefront of translating viral immunology into tangible clinical protocols, offering a promising path toward more personalized and less morbid cancer care.
Research Focus
Key Achievements
Top Papers
- 1